Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix
July 21, 2023 08:00 ET
|
Fresh Tracks Therapeutics, Inc.
BOULDER, Colo., July 21, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform...
Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023 16:01 ET
|
Fresh Tracks Therapeutics, Inc.
Reported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023 Ongoing evaluation of strategic options to further develop FRTX-02 and...
Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 30, 2023 16:01 ET
|
Fresh Tracks Therapeutics, Inc.
Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for...
Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02
March 07, 2023 16:01 ET
|
Fresh Tracks Therapeutics, Inc.
FRTX-02 was generally safe and well tolerated within the potential therapeutic dose range, meeting the study’s primary objectives Plasma concentrations within the potential therapeutic dose range...
Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer
January 27, 2023 08:00 ET
|
Fresh Tracks Therapeutics, Inc.
BOULDER, Colo., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“Fresh Tracks” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing...
Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor, in the Peer-Reviewed Journal of Translational Autoimmunity
January 11, 2023 08:00 ET
|
Fresh Tracks Therapeutics, Inc.
BOULDER, Colo., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“Fresh Tracks” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing...
Fresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022 16:05 ET
|
Fresh Tracks Therapeutics, Inc.
Phase 1 study of FRTX-02 progressing well, with the SAD portion complete and MAD portion underway Remain on track to report SAD and MAD topline results from the Phase 1 study of FRTX-02 by early 2023...
Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022
November 03, 2022 16:05 ET
|
Fresh Tracks Therapeutics, Inc.
BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“Fresh Tracks Therapeutics” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to...
Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02
September 13, 2022 08:00 ET
|
Fresh Tracks Therapeutics, Inc.
FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing On track to report SAD and MAD topline results from FRTX-02...
Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics
September 07, 2022 08:00 ET
|
Fresh Tracks Therapeutics, Inc.
New name, logo, website, and branding reflect the Company’s strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under...